Skip to main content

Table 1 Comparison of patients’ characteristics between training cohort and validation cohort

From: Development and validation of a radiomics-based model to predict local progression-free survival after chemo-radiotherapy in patients with esophageal squamous cell cancer

Variables Training cohort (n = 155) Validation cohort (n = 66) χ2/t p
Age (years), Mean ± SD 65.7147 ± 9.74 64.73 ± 10.16 0.678 0.499
Gender 0.342 0.559
 Male 116 (74.8) 45 (68.2)
 Female 39 (25.2) 21 (31.8)
Tumor location 5.814 0.121
 Cervical 6 (3.9) 8 (12.1)
 Upper thoracic 34 (21.9) 16 (24.2)
 Middle thoracic 91 (58.7) 33 (50.00)
 Lower thoracic 24 (15.5) 9 (13.6)
T stage 3.193 0.363
 T1 2 (1.3) 0 (0)
 T2 11 (7.1) 9 (13.6)
 T3 66 (42.6) 27 (40.9)
 T4 76 (49.0) 30 (45.5)
N stage 1.856 0.603
 N0 20 (12.9) 13 (19.7)
 N1 70 (45.2) 28 (42.4)
 N2 55 (35.5) 22 (33.3)
 N3 10 (6.5) 3 (4.5)
Clinical stage 3.152 0.369
 I 2 (1.3) 0 (0)
 II 15 (9.7) 11 (16.7)
 III 88 (56.8) 37 (56.1)
 Iva 50 (32.3) 18 (27.3)
Radiation dose, Median (range) 64 (60–66) 64 (60–66) − 0.920 0.358
LDH group 1.282 0.258
 High 88 (56.8) 32 (48.5)
 Normal 67 (43.2) 34 (51.5)
NLR, Median (range) 2.73 (1.96–3.71) 2.76 (2.00–3.63) − 0.448 0.654
PLR, Median (range) 137.78 (100.56–181.43) 138.87 (101.31–182.26) − 0.344 0.731
CR ratio 52 (33.5) 26 (39.4) 0.693 0.405
Rad-score, Mean ± SD − 0.0289 ± 0.35 − 0.058 ± 0.538 0.474 0.636